Heart Disease Clinical Trials in Salt Lake City

Showing 281-300 of 396 trials

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592

VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.

PsoriasisCardiovascular Disease

University of Pennsylvania81 participantsStarted Apr 2013

Sacramento, California, United States • Denver, Colorado, United States • Bethesda, Maryland, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

NCT00088179

During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.

Coronary Artery Disease

Alexion Pharmaceuticals, Inc.4,000 participantsStarted Jul 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +185 more locations

Vascular Inflammation in Psoriasis - Extension Study

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Heart Disease Trials in Other Cities

Muscle Afferent Feedback Effects in Patients With Heart Failure

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Expression of Longevity Genes in Response to Extended Fasting

Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure

Naltrexone/Bupropion Cardiovascular Outcomes Study

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

An Observational Study of Cholesterol in Coronary Arteries

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

Statin Choice Decision Aid Implementation First Phase

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017

Other Conditions in Salt Lake City